Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(100.0%)
3Total
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06943573Phase 3Not Yet Recruiting

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

Role: lead

NCT02731612Phase 3Completed

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Role: lead

NCT04771299Phase 3Terminated

Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients

Role: lead

All 3 trials loaded